Lightnews — Scholar-powered news

The ASCO Post @ascopost.bsky.social · 16h

In older adults with early-stage cervical cancer, adherence to recommended surgery or radiation significantly improved survival.

In @jamanetworkopen.com, Suk et al urge addressing barriers to adherence to reduce mortality in aging populations.

ascopost.com/news/october...

1

The ASCO Post @ascopost.bsky.social · 1d

Study of 9/11 WTC first responders shows risks of toxic particulates from environmental catastrophes:
6× higher leukemia risk in responders with clonal hematopoiesis

But, targeting IL1RAP could reduce inflammation-driven disorders

ascopost.com/news/october...

9/11 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers

“Our findings provide new insights into the long-term health impacts of environmental catastrophes, such as wildfires, and suggest targeted interventions for those affected by 9/11 or similar disaster...

ascopost.com

The ASCO Post @ascopost.bsky.social · 4d

The @usfda.bsky.social has approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma

FDA approval based on findings from the C-POST study:
Median DFS not reached vs 49.4 months w/ placebo (HR = 0.32; P < .0001)

ascopost.com/news/october...

PD-1 Inhibitor Approved for Adjuvant Treatment of CSCC

The FDA has approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation therapy.

ascopost.com

The ASCO Post @ascopost.bsky.social · 5d

Patients with HER2+ mCRC receiving chemo + bevacizumab/anti-EGFR therapy face worse survival than pts with HER2– disease
- HR for PFS = 1.31 (P = .02)
- HR for OS = 1.37 (P = .01)

Corresponding author: Chiara Cremolini, MD, PhD

ascopost.com/news/october...

Impact of HER2-Receptor Status in mCRC Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs

In an analysis reported in the Journal of Clinical Oncology, Germani et al identified the impact of HER2 status in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy plus either ...

ascopost.com

The ASCO Post @ascopost.bsky.social · 6d

Cases of kidney cancer projected to double by 2050 globally due to modifiable risk factors.
From Alexander Kutikov, MD, FACS, et al
ascopost.com/news/october...

Kidney Cancer Cases Expected to Double by 2050

A recent review tracked and projected the future global epidemiology of kidney cancer, examining its incidence, mortality, survival, genetic predisposition, and risk factors.

ascopost.com

1

The ASCO Post @ascopost.bsky.social · 7d

BART Trial Presented at the ASTRO Annual Meeting: Adjuvant RT after cystectomy + chemo in MIBC improves survival with no excess grade ≥3 toxicity

One of the first large randomized trials to show meaningful pelvic relapse reductions, says Vedang Murthy, MD

ascopost.com/news/septemb...

Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer

Adjuvant radiation therapy after radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from ...

ascopost.com

1

The ASCO Post @ascopost.bsky.social · 8d

Phase II LUNAR Trial: PSMA-targeted radiopharmaceutical plus SBRT improved PFS in pts with oligometastatic prostate cancer (18 vs 7 mo), which helped to delay ADT by 24 months

Presented by Amar U. Kishan, MD, at the ASTRO Annual Meeting @astro-org.bsky.social

ascopost.com/news/septemb...

Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease

In prostate cancer, radiopharmaceuticals typically target PSMA, delivering precise doses of radiation directly to tumors; these medicines are currently approved for later-stage prostate cancer. The LU...

ascopost.com

2 1

The ASCO Post @ascopost.bsky.social · 11d

On Sept 29th, Anthony Letai, MD, PhD, was sworn in as the new Director of the National Cancer Institute (NCI).

He is known for his venetoclax research, predictive biomarker development, and work in apoptosis.

ascopost.com/news/septemb...

1

The ASCO Post @ascopost.bsky.social · 12d

PRISM Trial: first large-scale randomized study of AI in breast cancer screening in the US

📏 Will evaluate effects on cancer detection, recall rates, & radiologist and patient trust

👩‍⚕️Co-PI: Joann Elmore, MD, MPH

🔗 ascopost.com/news/septemb...

1 2

The ASCO Post @ascopost.bsky.social · 13d

Study suggests that dietary supplement nicotinamide associated with reduced risk of new skin cancer development.
✅ Greatest benefit seen when taken after first skin cancer

From Kimberly Breglio, MD, PhD, et al

ascopost.com/news/septemb...

Can Nicotinamide Lessen the Risk of Skin Cancer Development?

A retrospective study aimed to determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients.

ascopost.com

1

The ASCO Post @ascopost.bsky.social · 14d

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell RCC led to extended median PFS without compromising safety.

The median systemic therapy–free survival was 34 months.

Insights from Chad Tang, MD, et al here: ascopost.com/news/septemb...

2

The ASCO Post @ascopost.bsky.social · 15d

In the latest issue of The ASCO Post, Stuart M. Lichtman, MD, explains how the new @jco-asco.bsky.social guidelines could improve clinical trial reporting and enhanced care for older patients with cancer.

Read more here: ascopost.com/issues/septe...

1

The ASCO Post @ascopost.bsky.social · 18d

The September 25 issue of The ASCO Post features insights from @iaslc.bsky.social's WCLC and ASCO 2025, perspectives on palliative care integration, geriatric inclusivity in cancer trial data, accelerated aging in childhood cancer survivors, and MORE

Full issue here: ascopost.com/issues/septe...

2 2

The ASCO Post @ascopost.bsky.social · 20d

🧠 Association found between moderate/severe traumatic brain injury and risk of developing malignant brain tumors in US civilians (HR = 1.67)

🔢 Relationship confirmed in meta-analysis

✍️ Saef Izzy, MD
ascopost.com/news/septemb...

1

The ASCO Post @ascopost.bsky.social · 22d

Three leading cancer organizations @ascocancer.bsky.social, @astro-org.bsky.social, & @socsurgonc.bsky.social updated guidelines on postmastectomy radiotherapy based on new evidence.

Expert panel co-chaired by Rachel B. Jimenez, MD & Kathleen C. Horst, MD

ascopost.com/news/septemb...

2

The ASCO Post @ascopost.bsky.social · 25d

New report from the American Cancer Society, and lead author Tyler Kratzer, MPH, shows:
- Prostate cancer incidence rising 3%/yr (2014–2021), w/ advanced-stage up 4.6-4.8%/yr
- Mortality decline slowed to 0.6%/yr
- Major disparities persist

ascopost.com/news/septemb...

The ASCO Post @ascopost.bsky.social · 26d

Optimizing CAR T-cell therapy: one size does not fit all, says Nirav H. Shah, MD, MSHP

Antigen targeting should align with disease characteristics of B-cell malignancies

ascopost.com/issues/septe...

1 4

The ASCO Post @ascopost.bsky.social · 27d

Real-world data on T-DXd rechallenge after grade 1 ILD: pts with breast cancer continued treatment for several months with low ILD recurrence rates

Study authors Kelsey Natsuhara, MD, @hoperugo.bsky.social, et al

ascopost.com/issues/septe...

2

The ASCO Post @ascopost.bsky.social · 28d

In the September 10 issue of The ASCO Post:
Kenneth C. Anderson, MD of @danafarbernews.bsky.social
offers insights on the CARTITUDE-1 trial and future research for multiple myeloma
ascopost.com/issues/septe...

1

The ASCO Post @ascopost.bsky.social · Sep 11

The @fda.gov has approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with CIS with/without papillary tumors.

In the SunRISe-1 trial: complete responses reported in 82%

ascopost.com/news/septemb...

1 2

The ASCO Post @ascopost.bsky.social · Sep 9

The Cancer Planners Forum 2025, hosted by @uiccofficial.bsky.social with @who.int, @iaeaorg.bsky.social, etc held in May 2025 raised urgent global needs for cancer control plans.

Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges

ascopost.com/news/septemb...

1 1

The ASCO Post @ascopost.bsky.social · Aug 26

Inside the August Issue of The ASCO Post: insights from the 2025 EHA Congress, 2025 ASCO Annual Meeting, impacts of the Inflation Reduction Act, cardio-oncology risks, and treatment advances in head and neck cancers #hncsm

Read the full issue here: ascopost.com/issues/augus...

1 1

The ASCO Post @ascopost.bsky.social · Aug 21

New cohort data show post-mastectomy implant reconstructions carry a low risk of non-Hodgkin lymphomas of the breast, with a standardized incidence ratio of 5.03.

Corresponding author Alfred Neugut, MD, PhD
@columbiamed.bsky.social

ascopost.com/news/august-...

1 1

The ASCO Post @ascopost.bsky.social · Aug 18

Polish study showed reliance on AI led to decreased adenoma detection by endoscopists in non-AI assisted colonoscopies (28.4% > 22.4%) ⚠️
Study by Krzysztof Budzyń, MD; Yuichi Mori, MD; et al
Commentary from Omer Ahmad, MD

ascopost.com/news/august-...

The ASCO Post @ascopost.bsky.social · Aug 15

Largest-ever single donation announced: Nike co-founder Phil Knight & Penny Knight to gift $2B to OHSU Knight Cancer Institute, inspired by its president Brian Druker, MD

Donation will allow for full support for every patient, accelerated diagnostics, access to trials

ascopost.com/news/august-...

1